Novartis antibody pacibekitug cuts inflammation markers in Phase 2 trial
A mid-stage study showed Novartis’s drug pacibekitug significantly reduced inflammation biomarkers, sparking interest in its potential heart benefits.
In the Phase 2 TRANQUILITY trial, the IL-6-targeting antibody pacibekitug produced dose-related declines in several inflammation markers. Results were unveiled at the European Society of Cardiology’s annual meeting in Munich. Researchers highlighted the sustained biomarker drops as evidence of biological activity. The company now faces decisions on further development toward cardiovascular indications.
Why it matters
If successful, the drug could offer a new way to treat heart disease by targeting inflammation.
In this story
NovartispacibekituginflammationIL-6Phase 2cardiovascularbiomarkerEuropean Society of CardiologyMunich
